Arcus Biosciences, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Arcus discontinued Phase 3 PACIFIC-8 trial (domvanalimab + durvalumab in NSCLC) following earlier discontinuations of STAR-221 and STAR-121 trials. Gilead relinquished three board seats effective August 5, 2026. Arcus refocuses on casdatifan development across ccRCC treatment lines via three new clinical collaborations (BMS, Summit, AVEO) and expects $15M milestone from Taiho in Q3 2026. Cash position: $775M (June 30, 2026) vs. $1.01B (Dec 31, 2025); runway to at least H2 2028.
Why this rating
Program termination is material portfolio contraction (eliminates ~$4-5M quarterly R&D spend) but hedged by casdatifan acceleration and modest milestone income. Cash burn and loss ($91M Q2 loss) moderate relative to $775M balance. Strategic pivot, not existential crisis.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.